文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

新型C2结构域结合CD33xCD3双特异性抗体抗急性髓系白血病

A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia.
PubMed 文献 · Blood Adv · 2020-01-01

研究开发了靶向CD33的C2结构域和CD3的双特异性抗体JNJ-67571244,可在体外诱导CD33+ AML细胞毒性和T细胞活化,在体内小鼠模型中显示抗肿瘤活性,并清除AML患者血液中的CD33+原始细胞。该抗体在食蟹猴中耐受良好(至30 mg/kg),且细胞毒性不受rs12459419 SNP基因型影响。

要点

  • JNJ-67571244靶向CD33的C2结构域,不受V结构域SNP rs12459419影响
  • 体外诱导CD33+ AML细胞毒性与T细胞活化、细胞因子释放
  • 食蟹猴中至30 mg/kg耐受良好,已进入复发/难治AML和高危MDS的1期试验

核心结论

  • JNJ-67571244通过结合CD33的C2结构域和CD3重定向T细胞,对CD33+ AML发挥细胞毒性,且不受SNP基因型限制,支持其进入1期临床试验。

研究设计与样本

  • 临床前研究:构建新型人源CD33xCD3双特异性抗体JNJ-67571244,开展体外细胞实验、人AML小鼠模型和食蟹猴毒理研究。

主要发现

  • JNJ-67571244特异性结合CD33表达细胞,体外诱导CD33+ AML细胞系细胞毒性并伴T细胞活化和细胞因子释放。
  • 在播散性和皮下人AML小鼠模型中显示有统计学意义的抗肿瘤活性。
  • 可清除AML患者血液样本中的CD33+原始细胞并伴T细胞活化。
  • 在食蟹猴中引起T细胞活化、短暂细胞因子释放和CD33+白细胞持续减少。

关键数值与推荐

  • CD33在90%的AML患者中表达,其胞外部分含V结构域和C2结构域。
  • SNP rs12459419(C > T)导致含V结构域的CD33表达降低,并限制V结构域结合抗CD33抗体的疗效。
  • JNJ-67571244在食蟹猴中至30 mg/kg耐受良好。
  • JNJ-67571244对细胞系和原代样本的细胞毒性不受SNP基因型影响。

临床怎么用

  • 该抗体目前处于复发/难治AML和高危MDS的1期临床试验,临床使用尚待试验结果。

局限性

  • 原文为临床前研究,尚无患者疗效和安全性数据;人体有效剂量与风险未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD33 is expressed in 90% of patients with acute myeloid leukemia (AML), and its extracellular portion consists of a V domain and a C2 domain. A recent study showed that a single nucleotide polymorphism (SNP), rs12459419 (C > T), results in the reduced expression of V domain-containing CD33 and limited efficacy of V domain-binding anti-CD33 antibodies. We developed JNJ-67571244, a novel human bispecific antibody capable of binding to the C2 domain of CD33 and to CD3, to induce T-cell recruitment and CD33+ tumor cell cytotoxicity independently of their SNP genotype status. JNJ-67571244 specifically binds to CD33-expressing target cells and induces cytotoxicity of CD33+ AML cell lines in vitro along with T-cell activation and cytokine release. JNJ-67571244 also exhibited statistically significant antitumor activity in vivo in established disseminated and subcutaneous mouse models of human AML. Furthermore, this antibody depletes CD33+ blasts in AML patient blood samples with concurrent T-cell activation. JNJ-67571244 also cross-reacts with cynomolgus monkey CD33 and CD3, and dosing of JNJ-67571244 in cynomolgus monkeys resulted in T-cell activation, transient cytokine release, and sustained reduction in CD33+ leukocyte populations. JNJ-67571244 was well tolerated in cynomolgus monkeys up to 30 mg/kg. Lastly, JNJ-67571244 mediated efficient cytotoxicity of cell lines and primary samples regardless of their SNP genotype status, suggesting a potential therapeutic benefit over other V-binding antibodies. JNJ-67571244 is currently in phase 1 clinical trials in patients with relapsed/refractory AML and high-risk myelodysplastic syndrome.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Nair-Gupta P, Diem M, Reeves D, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020. PMID: 32150609. doi:10.1182/bloodadvances.2019001188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。